Table 1.
Published case reports describing MS patients infected by SARS-CoV-2 after alemtuzumab administration. RR relapsing remitting, NA not available, ALZ alemtuzumab, IFN interferon, DF dimethyl fumarate, NTZ natalizumab, FING fingolimod, CLA cladribine
| Article | Age | Sex | Comorbidities | MS | EDSS | ALZ cycles | Last ALZ cycle (months) | Previous DMT | Last lymphocytes count/mm3 | Severe COVID diseases | Symptoms | Hospitalization | Outcome | SARS-CoV2-ab |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fernandez-Diaz et al. 3 | 43 | m | No | RR | 0 | II | 11 | IFN, FING | 550 | No | Fever, cough, myalgia, shortness of breath | No | Recovered | Positive |
| Fernandez-Diaz et al. 3 | 30 | f | Ex smoker | RR | 2.5 | II | 0.25 | No | 0 | No | Fever, cough, dyspnea | 4 days | Recovered | Positive |
| Carandini et al. 4 | 25 | f | No | RR | NA | II | 0.25 | No | 99 | No | Fever, cough, fatigue | No | Recovered | NA |
| Guevara et al. 5 | 35 | m | No | RR | 1.0 | II | 2.5 | No | 680 | No | Fever | No | Recovered | NA |
| Fiorella et al. 6 | 24 | f | No | RR | 0 | II | 3 | No | 930 | No | Cough, sore throat, myalgia | No | Recovered | Positive |
| Matias Guiu et al. 7 | 54 | f | NA | NA | NA | II | 12 | NA | 1000 | No | Asymptomatic | No | Recovered | NA |
| Matias Guiu et al. 7 | 51 | f | NA | NA | NA | II | 12 | NA | 500 | No | Mild symptoms | No | Recovered | NA |
| Sormani et al. 8, 3 patients | NA | NA | NA | NA | NA | NA | NA | NA | NA | No | NA | No | Recovered | NA |
| Iovino et al. 9 | 24 | f | Heart valve repair | RR | 3.0 | I | 4 | IFN, DF, NTZ, CLA | 400 | No | No | No | Recovered | Positive |
| Our report | 30 | f | No | RR | 1.0 | II | 4 | No | 630 | No | cough, sternal chest pain and hyposmia | No | Recovered | Positive |
*Among 14 patients treated with alemtuzumab presented in the mentioned paper as suspected cases, we included only the 3 patients with confirmed SARS-CoV-2 infection